Overview

  • Product nameAnti-CBL (phospho Y774) antibody
    See all CBL primary antibodies
  • Description
    Rabbit polyclonal to CBL (phospho Y774)
  • SpecificityRecognises CBL when phosphorylated at these sites: Human: Tyr774; Mouse: Tyr780; Rat: Tyr888
  • Tested applicationsSuitable for: WB, ELISA, IHC-Pmore details
  • Species reactivity
    Reacts with: Human
    Predicted to work with: Mouse, Rat
  • Immunogen

    Synthetic phosphopeptide derived from human CBL around the phosphorylation site of tyrosine 774 (D-G-YP-D-V).

  • Positive control
    • HeLa cells extracts Human breast carcinoma tissue
  • General notesStable at -20°C for 1 year

Properties

Applications

Our Abpromise guarantee covers the use of ab58505 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB 1/500 - 1/1000. Detects a band of approximately 100 kDa (predicted molecular weight: 99 kDa).
ELISA 1/5000.
IHC-P Use at an assay dependent concentration.

Target

  • FunctionParticipates in signal transduction in hematopoietic cells. Adapter protein that functions as a negative regulator of many signaling pathways that start from receptors at the cell surface. Acts as an E3 ubiquitin-protein ligase, which accepts ubiquitin from specific E2 ubiquitin-conjugating enzymes, and then transfers it to substrates promoting their degradation by the proteasome. Recognizes activated receptor tyrosine kinases, including PDGFA, EGF and CSF1, and terminates signaling.
  • PathwayProtein modification; protein ubiquitination.
  • Involvement in diseaseDefects in CBL are the cause of Noonan syndrome-like disorder (NSL) [MIM:613563]. NSL is a syndrome characterized by a phenotype reminiscent of Noonan syndrome. Clinical features are highly variable, including facial dysmorphism, short neck, developmental delay, hyperextensible joints and thorax abnormalities with widely spaced nipples. The facial features consist of triangular face with hypertelorism, large low-set ears, ptosis, and flat nasal bridge. Some patients manifest cardiac defects.
  • Sequence similaritiesContains 1 Cbl-PTB (Cbl-type phosphotyrosine-binding) domain.
    Contains 1 RING-type zinc finger.
    Contains 1 UBA domain.
  • DomainThe RING-type zinc finger domain mediates binding to an E2 ubiquitin-conjugating enzyme.
    The N-terminus is composed of the phosphotyrosine binding (PTB) domain, a short linker region and the RING-type zinc finger. The PTB domain, which is also called TKB (tyrosine kinase binding) domain, is composed of three different subdomains: a four-helix bundle (4H), a calcium-binding EF hand and a divergent SH2 domain.
  • Post-translational
    modifications
    Phosphorylated on tyrosine residues by EGFR, SYK, FYN and ZAP70 (By similarity). Phosphorylated on tyrosine residues by INSR.
  • Cellular localizationCytoplasm.
  • Information by UniProt
  • Database links
  • Alternative names
    • 4732447J05Rik antibody
    • C CBL antibody
    • Cas Br M (murine) ecotropic retroviral transforming sequence antibody
    • Casitas B lineage lymphoma proto oncogene antibody
    • Casitas B-lineage lymphoma proto-oncogene antibody
    • CBL 2 antibody
    • cbl antibody
    • CBL_HUMAN antibody
    • CBL2 antibody
    • E3 ubiquitin protein ligase CBL antibody
    • E3 ubiquitin-protein ligase CBL antibody
    • Oncogene CBL2 antibody
    • Proto oncogene c CBL antibody
    • Proto-oncogene c-CBL antibody
    • RGD1561386 antibody
    • RING finger protein 55 antibody
    • RNF55 antibody
    • Signal transduction protein CBL antibody
    see all

Anti-CBL (phospho Y774) antibody images

  • All lanes : Anti-CBL (phospho Y774) antibody (ab58505) at 1/500 dilution

    Lane 1 : Extracts from HeLa cells, treated with EGF (200ng/ml, 30mins)
    Lane 2 : Extracts from HeLa cells, treated with EGF (200ng/ml, 30mins), plus immunising peptide


    Predicted band size : 99 kDa
    Observed band size : 100 kDa (why is the actual band size different from the predicted?)
  • ab58505 at a 1/50 dilution staining CBL (phosphorylated at tyrosine 774) in Human breast carcinoma tissue.
  • ab58505, at a 1/50 dilution, plus immunising peptide, staining CBL (phosphorylated at tyrosine 774) in Human breast carcinoma tissue.

References for Anti-CBL (phospho Y774) antibody (ab58505)

ab58505 has not yet been referenced specifically in any publications.

Product Wall

There are currently no Abreviews or Questions for ab58505.
Please use the links above to contact us or submit feedback about this product.

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"